Top

Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 15-02-2022 | Solid Tumor | Original Article – Clinical Oncology

Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial

Authors: Yanshuo Cao, Ming Lu, Yu Sun, Jifang Gong, Jie Li, Zhihao Lu, Jian Li, Xiaotian Zhang, Yan Li, Zhi Peng, Jun Zhou, Xicheng Wang, Lin Shen

Published in: Journal of Cancer Research and Clinical Oncology | Issue 2/2023

Abstract

Purpose

This phase 1 trial evaluated the safety, preliminary efficacy, and pharmacokinetics of surufatinib, a small molecular tyrosine kinase inhibitor, combined with toripalimab, a programmed cell death protein-1 antibody, in patients with advanced solid tumors.

Methods

This is an open-label, dose-escalation and expansion study in patients with solid tumors who had failed standard therapies or had no effective treatment. In the dose-escalation stage, patients were treated with surufatinib, at dose levels of 200, 250, or 300 mg once daily (QD) in combination with toripalimab 240 mg, every 3 weeks (Q3W), to estimate maximum tolerated dose. Additional patients were enrolled in the dose expansion stage to further assess the efficacy, safety, and pharmacokinetics profile. Recommended phase 2 dose (RP2D) was determined based on the safety, tolerability, and preliminary efficacy from dose-escalation and expansion stages.

Results

From Feb 14, 2019 to Dec 20, 2020, 33 patients were screened, of which 30 patients were enrolled. One patient in the 300 mg cohort experienced dose limited toxicity, a grade 3 hyperthyroidism. The most frequent treatment-related adverse events of grade ≥ 3 were hypertension (20.0%), transaminases increased (13.3%), and blood bilirubin increased (13.3%). No treatment-related death or treatment discontinuation was identified. The RP2D was determined to be surufatinib 250 mg QD plus toripalimab 240 mg Q3W. Objective response rate was 24.1% (95% confidence interval 10.3‒43.5%) in this study.

Conclusions

Surufatinib plus toripalimab was well tolerated, with no unexpected safety signals, and showed preliminary anti-tumor activity in patients with advanced solid tumors.

Trial registration

Clinicaltrials.gov Identifier: NCT03879057; registration date: March 18, 2019.

Available only for authorised users

Abida W, Cheng ML, Armenia J et al (2019) Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol 5(4):471–478. https://doi.org/10.1001/jamaoncol.2018.5801CrossRefPubMed

Atkins MB, Plimack ER, Puzanov I et al (2018) Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol 19(3):405–415. https://doi.org/10.1016/S1470-2045(18)30081-0CrossRefPubMedPubMedCentral

Buckanovich RJ, Facciabene A, Kim S et al (2008) Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 14(1):28–36. https://doi.org/10.1038/nm1699CrossRefPubMed

Carmeliet P, Jain RK (2020) Angiogenesis in cancer and other diseases. Nature 407:249–257. https://doi.org/10.1038/35025220CrossRef

Chen J, Ji Q, Bai C et al (2020) Surufatinib in Chinese patients with locally advanced or metastatic differentiated thyroid cancer and medullary thyroid cancer: a multicenter, open-label, phase II trial. Thyroid 30(9):1245–1253. https://doi.org/10.1089/thy.2019.0453CrossRefPubMed

Finn RS, Ikeda M, Zhu AX et al (2020) Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol 38(26):2960–2970. https://doi.org/10.1200/JCO.20.00808CrossRefPubMedPubMedCentral

Fukuoka S, Hara H, Takahashi N et al (2020) Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol 38(18):2053–2061. https://doi.org/10.1200/JCO.19.03296CrossRefPubMed

Gunturi A, McDermott DF (2014) Potential of new therapies like anti-PD1 in kidney cancer. Curr Treat Options Oncol 15(1):137–146. https://doi.org/10.1007/s11864-013-0268-yCrossRefPubMed

Herbst RS, Arkenau HT, Santana-Davila R et al (2019) Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncol 20(8):1109–1123. https://doi.org/10.1016/S1470-2045(19)30458-9CrossRefPubMed

Keam SJ (2019) Toripalimab: first global approval. Drugs 79(5):573–578. https://doi.org/10.1007/s40265-019-01076-2CrossRefPubMed

Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509–2520. https://doi.org/10.1056/NEJMoa1500596CrossRefPubMedPubMedCentral

Lu M, Zhang P, Zhang Y et al (2020) Efficacy, safety, and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase Ib trial. Clin Cancer Res 26(10):2337–2345. https://doi.org/10.1158/1078-0432.CCR-19-4000CrossRefPubMed

Makker V, Rasco D, Vogelzang NJ et al (2019) Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 20(5):711–718. https://doi.org/10.1016/S1470-2045(19)30020-8CrossRefPubMed

Manegold C, Dingemans AC, Gray JE et al (2017) The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J Thorac Oncol 12(2):194–207. https://doi.org/10.1016/j.jtho.2016.10.003CrossRefPubMed

McGarrah PW, Leventakos K, Hobday TJ et al (2018) Efficacy of 2nd-line chemotherapy in patients with poorly differentiated, high grade extrapulmonary neuroendocrine carcinoma (PD NEC). J Clin Oncol 36(15_suppl):e16162CrossRef

Mo DC, Luo PH, Huang SX, Wang HL, Huang JF (2021) Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: a systematic review. Int Immunopharmacol 91:107281. https://doi.org/10.1016/j.intimp.2020.107281CrossRefPubMed

Motzer RJ, Penkov K, Haanen J et al (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1103–1115. https://doi.org/10.1056/NEJMoa1816047CrossRefPubMedPubMedCentral

Ninomiya K, Hotta K (2018) Pembrolizumab for the first-line treatment of non-small cell lung cancer. Expert Opin Biol Ther 18(10):1015–1021. https://doi.org/10.1080/14712598.2018.1522300CrossRefPubMed

Oliveira AF, Bretes L, Furtado I (2019) Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer. Front Oncol 9:396. https://doi.org/10.3389/fonc.2019.00396CrossRefPubMedPubMedCentral

Powles T, Plimack E, Soulières D et al (2020) (2020) Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol 21(12):1563–1573CrossRefPubMed

Rini BI, Powles T, Atkins MB et al (2019) Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 393(10189):2404–2415. https://doi.org/10.1016/S0140-6736(19)30723-8CrossRefPubMed

Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320–330. https://doi.org/10.1056/NEJMoa1412082CrossRefPubMed

Sharma P, Allison JP (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161:205–214. https://doi.org/10.1016/j.cell.2015.03.030CrossRefPubMedPubMedCentral

Sheng X, Yan X, Chi Z et al (2019) Axitinib in combination with toripalimab, a humanized immunoglobulin g4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase Ib trial. J Clin Oncol 37(32):2987–2999. https://doi.org/10.1200/JCO.19.00210CrossRefPubMedPubMedCentral

Socinski MA, Jotte RM, Cappuzzo F et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378(24):2288–2301. https://doi.org/10.1056/NEJMoa1716948CrossRefPubMed

Stanley ER, Chen DM, Lin HS (1978) Induction of macrophage production and proliferation by a purified colony stimulating factor. Nature 274(5667):168–170. https://doi.org/10.1038/274168a0CrossRefPubMed

Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454. https://doi.org/10.1056/NEJMoa1200690CrossRefPubMedPubMedCentral

Tsao MS, Kerr KM, Kockx M et al (2018) PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol 13(9):1302–1311. https://doi.org/10.1016/j.jtho.2018.05.013CrossRefPubMedPubMedCentral

Wang F, Wei XL, Wang FH et al (2019) Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol 30(9):1479–1486. https://doi.org/10.1093/annonc/mdz197CrossRefPubMedPubMedCentral

Xu J, Li J, Bai C et al (2019) Surufatinib in advanced well-differentiated neuroendocrine tumors: a multicenter, single-arm, open-label, phase Ib/II trial. Clin Cancer Res 25(12):3486–3494. https://doi.org/10.1158/1078-0432.CCR-18-2994CrossRefPubMed

Xu J, Shen L, Zhou Z et al (2020a) Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21(11):1500–1512. https://doi.org/10.1016/S1470-2045(20)30496-4CrossRefPubMed

Xu J, Shen L, Bai C et al (2020b) Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21(11):1489–1499. https://doi.org/10.1016/S1470-2045(20)30493-9CrossRefPubMed

Yang J, Dong L, Yang S et al (2020) Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study. Eur J Cancer 130:182–192. https://doi.org/10.1016/j.ejca.2020.01.028CrossRefPubMed

Zhou J, Ni J, Cheng M et al (2017) Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR-1 and CSF-1R kinases. AACR Abstract 77(13). https://doi.org/10.1158/1538-7445.AM2017-4187

Title: Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
Authors: Yanshuo Cao
Ming Lu
Yu Sun
Jifang Gong
Jie Li
Zhihao Lu
Jian Li
Xiaotian Zhang
Yan Li
Zhi Peng
Jun Zhou
Xicheng Wang
Lin Shen
Publication date: 15-02-2022
Publisher: Springer Berlin Heidelberg
Keyword: Solid Tumor
Published in: Journal of Cancer Research and Clinical Oncology / Issue 2/2023
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-021-03898-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 2/2023

Hyperbaric oxygen enhanced the chemotherapy of mitochondrial targeting molecule IR-780 in bladder cancer

Burnout among German oncologists: a cross-sectional study in cooperation with the Arbeitsgemeinschaft Internistische Onkologie Quality of Life Working Group

MicroRNA-profiling of miR-371~373- and miR-302/367-clusters in serum and cerebrospinal fluid identify patients with intracranial germ cell tumors

Case report: identification of EGFR R776H and FANCE R381H germline mutations in a patient with multiple pulmonary nodules

Risk factors and temporal patterns of recurrences in patients with vulvar cancer: implications for follow-up intervals and duration

The therapeutic effect of an autologous and allogenic mixed glioma cell lysate vaccine in a rat model

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials